Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial
Marios Georgakis, Research Group Leader and Physician at LMU Munich, Visiting Scientist at Broad Institute of MIT and Harvard University, shared on LinkedIn:
”In another win for genetically validated drug targets, a small molecule factor XI inhibitor on top of antiplatelet treatment, led to significant reductions (HR: 0.74, 95%CI: 0.65–0.84) in risk of recurrent ischemic stroke among patients with a non-cardioembolic ischemic stroke or TIA in the placebo-controlled OCEANIC-STROKE trial (12,327 patients).
As predicted by Mendelian randomization analyses several years ago, the benefit against ischemic stroke was not accompanied by an increase in risk of major bleeding, intracranial bleeding, or even minor bleeding.
This is unprecedented for an antithrombotic therapy.
Also interestingly, human genetic analyses had long supported no effects on myocardial infarction or coronary artery disease risk, which also lines up with the underwhelming available trial data in patients with acute myocardial infarction.”
Stay updated with Hemostasis Today.
-
May 25, 2026, 05:25Abdullah Mohsin: Automated Detection of DVT Using Deep Learning and Doppler Ultrasound
-
May 25, 2026, 05:07The Dual Role of PAI-1 Mutations in Bleeding and Thrombotic Disorders – ICHCC
-
May 25, 2026, 05:04Fibrinogen αC Domain Lysines Drive Plasminogen Binding and Plasmin Generation – JTH
-
May 25, 2026, 04:50Gülşah Türkoğlu: An Encouraging Momentum Around the Adoption of Resolutions on Stroke Care at WHA79
-
May 25, 2026, 04:47Krishnakant Prasad: A Quick Clinical Review of Renal Papillary Necrosis
-
May 25, 2026, 04:40Rajiv Kumar Jain: World Health Assembly Adopts First-Ever Global Resolution on Stroke Prevention and Care
-
May 25, 2026, 04:23Sarfraz Ahmad: Diagnostic and Therapeutic Challenges in ICA Aneurysm Presenting With Epistaxis
-
May 24, 2026, 17:48Flora Peyvandi: Crucial Role of Placental ADAMTS13 in Perinatal Survival
-
May 24, 2026, 17:13Mahtab Mashayekhi: The Evolving Role of Red Blood Cell Exchange in the Management of SCD